Bcr-Abl is the major cause and pathogenetic principle of chronic myeloid leukemia (CML). Bcr-Abl results from a chromosomal translocation that fuses the bcr and abl genes, thereby generating a constitutively active tyrosine kinase, which stimulates several signaling networks required for proliferation and survival. Bcr-Abl's oncogenic properties comprise both a kinase and a scaffold protein. 1 A number of Bcr-Abl interaction partners and downstream effectors have been described, improving our understanding of the signaling networks deranged in CML. The 'core interactome of Bcr-Abl' entails seven major interaction partners: GRB2, Shc1, Crk-l, c-Cbl, p85, Sts-1 and SHIP2. 2 The introduction of the Bcr-Abl tyrosine kinase inhibitor (TKI) Imatinib (Gleevec) has been a landmark in the treatment of CML. 3 However, the development of Imatinib resistance poses major challenges to the clinical management of CML, and although second-generation TKIs can block many Imatinib-resistant mutants they are ineffective against the common T315I mutation. An alternative strategy is to circumvent Imatinib resistance by targeting downstream pathways essential for transformation. 4 Therefore, it is important to fully understand these pathways. Large-scale (phospho)proteomics experiments have addressed the phosphoproteome of Bcr-Abl-positive cells, leading to the identification of an impressive number of serine/ threonine-phosphorylated sites (for example, Pan et al.
5
), although tyrosine-phosphorylation events remained underrepresented. However, many of the protein-protein interactions in the oncogenic Bcr-Abl network are dependent on tyrosine phosphorylation, either directly or indirectly through Bcr-Abl. 2 Here, we have enriched and identified phosphotyrosine peptides by quantitative mass spectrometry (qMS) 6 in order to examine the effect of Imatinib in the CML blast crisis cell line K562 (Supplementary Methods). First, the phosphorylation status and stability of several key proteins involved in Bcr-Abl signaling were evaluated in response to Imatinib. Although Imatinib strongly reduced tyrosine phosphorylation, none of the five investigated proteins were degraded (Figure 1a) . For qMS studies, we treated cells with 0, 1 and 10 mM Imatinib for 4 h as in previous studies (Figure 1b) . 5, 7 Cell lysates were subsequently digested with the proteases Lys-C and trypsin, followed by stable isotope dimethyl labeling of the resulting peptides. The labeling regime allows to distinguish three peptide pools (light, intermediate and heavy), which were mixed in equal concentrations. Subsequently, tyrosine-phosphorylated peptides were enriched by immunoprecipitation and analyzed by liquid chromatography-mass spectrometry (LC-MS). 6 Analysis of the quantitative changes in tyrosine phosphorylation yielded 201 unique quantifiable phosphotyrosine peptide triplets belonging to 141 proteins (Supplementary Table S1 ), by far exceeding all previous reports. 5, 7 Of these, 87 peptides showed at least a twofold downregulation after treatment with Imatinib (Supplementary Table S2 and Figure 1c) .
Imatinib significantly decreased the tyrosine phosphorylation of many peptides originating from Bcr-Abl and its core interactors (c-Cbl, CrkL and SHIP-2, Figure 1c) . Furthermore, several proteins that have been shown to have pivotal roles in Bcr-Abl-dependent signaling (Gab1, Gab2, Shc1, Crk, ERK-2, STAT5A/B and Yes) displayed reduced tyrosine phosphorylation, often on multiple sites. In addition, Src family kinase substrates exhibited reduced tyrosine phosphorylation, for example, Cortactin, Catenin delta-1, nPKC-delta and Paxillin. Finally, Imatinib reduced the tyrosine phosphorylation of several proteins involved in cytoskeletal regulation, such as MEMO1, Intersectin-2, Catenin delta-1, HEPL, GRF-1, Centaurin delta 2 and Plakophilin, which have not been linked to Bcr-Abl signaling.
A motif analysis on the sequences of significantly downregulated tyrosine-phosphorylated sites revealed a distinct enriched motif, YxxP (Figures 1d and e) . In total, 80% (23 out of 29) of the peptides harboring this phosphorylation motif were significantly downregulated upon Imatinib treatment. The YxxP Accepted article preview online 27 August 2012; advance online publication, 14 September 2012
Letters to the Editor motif resembles a classic binding site for SH2 domains, and a consensus target sequence for phosphorylation by Bcr-Abl. 8 Peptides found in our screen containing this motif include Bcr-Abl (Tyr115 and 128), STAT5A and B (Tyr682 and 699, respectively), several sites in the adaptor proteins Gab1 (Tyr259, 373 and 406) and Gab2 (Tyr266 and 409) and all four phosphotyrosine-containing peptides of the docking protein HEPL (Tyr174, 195, 244 and 329), indicating that the latter may represent a new Bcr-Abl substrate.
Most of the detected tyrosine phosphorylation sites on Bcr-Abl were completely abolished by Imatinib. Several of these have been linked to the activity of signaling pathways downstream of Bcr-Abl. 9 In contrast, two Bcr-Abl residues (Tyr253 and 257) were insensitive to Imatinib, suggesting that they may not be essential for downstream oncogenic signaling.
Several members of the Bcr-Abl core proteome 2 are adaptor/ scaffold proteins required for the generation of SH2-or PTBdomain-binding sites that lead to tightly regulated protein Overview of the quantitative proteomics workflow. Cells were treated with different doses of Imatinib (0, 1 and 10 mM) for 4 h, followed by cell lysis and protein digestion. The peptides from each Imatinib treatment were then differentially labeled using stable isotope dimethyl labeling. The three differentially labeled digests were combined, followed by simultaneous enrichment of tyrosine-phosphorylated peptides using immobilized phosphotyrosine-specific antibodies. The ). A small selection of peripheral interactors are depicted in blue. GAB2 (yellow) is used as flag-tagged entry point for interaction analysis upon Imatinib treatment. LC-MS/MS revealed the release of GAB2 from the Bcr-Abl core proteome, except GRB2 (bold red). Dashed lines indicate yet-to-beexplored lost/intact interactions within the Bcr-Abl Core proteome upon Imatinib treatment. (b) Mutation of all regulated GAB2 tyrosinephosphorylated residues to phenylalanine reveals abolishment of cell periphery localization of both GAB2 and probably also the Bcr-Abl Core interactome.
interactions.
10 Several of these peptides also contain the consensus sequence YxxP of the enriched phosphorylation motif (Figures 1c and d) . As these proteins bind to Bcr-Abl, the known and novel phosphorylation sites detected here may be putative Bcr-Abl substrates. The small adaptor protein GRB2, a member of the Bcr-Abl core proteome, has a key role in Bcr-Abl signaling through binding to phosphorylated Tyr177 on Bcr-Abl. This is required for activation of the Raf-MEK-ERK pathway in leukemic cells.
11 GRB2 interacts with the docking proteins Gab1 and Gab2 via GRB2's SH3 domain and the proline-rich regions in both Gab proteins (Supplementary Figure S1A) . 12 The observed tyrosine phosphorylations of both Gab1 and 2 are downregulated by Imatinib (Supplementary Table S2 ). Therefore, we quantitatively evaluated the changes in the Gab2 interactome in response to Imatinib treatment. Parallel FLAG immunoprecipitations from K562 cells transfected with either a empty FLAG vector or a FLAG-Gab2-encoding construct and treated with or without 10 mM Imatinib were performed. This affinity-based qMS approach revealed a severe alteration in the Gab2 interactome after Imatinib treatment (Figure 2 and Supplementary S1B-C and Table S3 ). Whereas GRB2 remained tightly bound, interactions between Gab2 and Shp2, as well as with components of the Bcr-Abl core interactome (for example, Bcr-Abl, SHIP-2 and Shc1), were severely disrupted, suggesting that the Gab2 interactome is dependent on the tyrosine phosphorylation state of this protein. Subsequent immunoprecipitation of endogenous Gab2 and western blot detection of interactors confirm the qMS results: Bcr-Abl, Shp2 and the p85 subunit of PI3 Kinase, all known Gab2 interactors, fail to coimmunoprecipitate with dephosphorylated Gab2 (Supplementary Figure S1D) . Gab2 has been previously shown to coimmunoprecipitate with Bcr-Abl in Ba/F3 cells. 13 Furthermore, the intracellular localization of Gab2 and the closely related Gab1 protein was evaluated by confocal microscopy. K562 cells were transfected with GFP-tagged constructs of wild-type or mutant Gab1 and Gab2, where all observed Imatinib-regulated phosphotyrosine residues were changed to phenylalanine. Wild-type GFP-Gab2 smoothly stained the circumference of the cell, whereas the mutant protein showed a severe alteration in localization with speckled staining of the cell periphery and cytosolic staining (Figure 2b and Supplementary Figure S2) . Similar changes in localization were observed with wild-type and mutant GFP-Gab1. Thus, tyrosine phosphorylation of Gab1 and Gab2 and the subsequent ability to promote the formation of a complex with Bcr-Abl and other core members appear to be required for appropriate membrane localization. These observations strongly advocate an involvement of Gab2 in the assembly of the Bcr-Abl signaling network at the plasma membrane and the ability of the core proteome to transform cells.
Several affected phosphotyrosine proteins identified in our screen can be linked to cytoskeletal processes, such as regulation of the actin cytoskeleton, cell migration or invasion. Among these, HEPL, a member of the p130 CAS family of scaffold proteins that is involved in cell migration, 14 showed dephosphorylation at four different sites in response to Imatinib treatment (Figure 1c) . Notably, HEPL was identified as a binding partner of Crk-l in K562 cells. 2 The closely related family members p130 CAS (BCAR1) and HEF1 (CAS-L) have both been identified as binding partners of Crk-l (and other Crk family members) and are downstream phosphorylation targets of Bcr-Abl.
14 In addition, we also identified CD2-associated protein, TRIP-6, Intersectin-2 and L-Plastin, all scaffold proteins involved in the modulation of the actin cytoskeleton, as being dephosphorylated by Imatinib treatment. These findings are in agreement with the literature suggesting that Bcr-Abl affects the cytoskeleton and cell motility, 14,15 potentially opening up new avenues of investigation to follow up the role of cytoskeletal changes in Bcr-Abl transformation.
In summary, to probe the effect of Imatinib on tyrosine kinase Bcr-Abl-positive cells, we applied a targeted qMS-based proteomics approach. We used phosphotyrosine-specific immunocapturing to systematically screen for Imatinib-dependent tyrosine phosphorylation events in K562 cells. Our data reveal that several core Bcr-Abl interactors are putative direct substrates. In following up a novel Imatinib-inhibited target, the adaptor protein Gab2 was found to regulate localization of the Bcr-Abl core complex to the plasma membrane in a phosphorylation-dependent manner, thus enabling us to add crucial new dimensions of detail to the Bcr-Abl signaling network. Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE)?
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Of the average 470 new cases of acute leukemia (AL) registered annually in France among children aged o15 years, 1 B90 are cases of acute myeloblastic leukemia (AML). Down's syndrome and other inheritable predisposing diseases explain only a small proportion of AML. Most childhood AML occurs before the age of 2 years, and researches have mainly focused on antenatal or early childhood exposures. 2 Advances in genetic technologies have enabled genome-wide association studies (GWAS) to be undertaken with the aim of identifying common single-nucleotide polymorphism variant alleles associated with small increases in AL risk. GWAS on acute lymphoblastic leukemia (ALL) have previously identified SNPs in ARID5B (rs7073837, rs10740055, rs7089424, rs10821936 and rs10994982) [3] [4] [5] [6] and IKZF1 (rs6964823, rs4132601, rs6944602 and rs11978267). [3] [4] [5] [6] In the present paper, the associations between childhood AML and the polymorphisms previously identified for ALL in ARID5B and IKZF1 were investigated in a candidate gene approach, using the data from the ESCALE case-control study.
The ESCALE study has been previously described in detail. 7, 8 Briefly, the cases were children o15 years old diagnosed with AL, lymphoma, central nervous system tumor or neuroblastoma in 2003-2004 and identified through the National Registry of Childhood Hematopoietic Malignancies. The study included 101 AML cases, 92% of the 110 eligible cases. A blood sample was obtained from 89 cases (88% of the included cases), 66 of whom were successfully genotyped. The ESCALE controls were randomly selected contemporaneously with the cases from French households with a landline telephone. Of the 2360 eligible controls identified, 1681 controls (71%) were included, 810 of whom provided buccal swab brushes, and 570 were successfully genotyped for candidate SNPs. The cases were genotyped on an Illumina 370K Quad BeadChip (San Diego, CA, USA) and the controls for 4868 candidate SNPs on Illumina Infinium iSelect custom beadchips (IntegraGen, Evry, France), including rs7073837, rs10740055 and rs7089424 in ARID5B, and rs6964823, rs4132601 and rs6944602 in IKZF1. Quality control excluded 109 ESCALE controls with an individual call rate o95% and 10 AML cases with individual call success o97%, low or high heterozygosity or discrepancies between stated sex and sexual chromosomes. Mean individual call rates were 99.9% for the cases and 98.5% for the controls. To control for potential population stratification bias, the analyses were restricted to the 51 cases and 442 controls who had at least two European-born grandparents. For the cases, the indicator predicted (with 98.2% sensitivity and 94.3% specificity) the CEPH classification, 'Caucasian derived', by principal component analysis, from 96 609 SNPs. It was assumed that having at least two European-born grandparents was an equally good proxy for the controls, for whom the SNPs were not available. The 51 AML cases of European descent consisted of 8 M1, 10 M2, 5 M3, 4 M4, 15 M5, 4 M7 and 5 unspecified AML.
The allelic dose of imputed SNPs was estimated and included as a continuous variable in the logistic models. Genotypic ORs were estimated using the homozygote common genotypes as references. Haplotypes were also inferred using the ExpectationMaximization algorithm implemented in PLINK, and posterior haplotype probabilities were used as weights in the logistic models. Table 1 presents the associations between AML and the candidate polymorphisms in IKZF1 and ARID5B. The allelic ORs for the associations between ARID5B SNPs and AML were greater than one, but the SNPs of ARID5B did not fit co-dominant models well: carrying the variant alleles of rs7073837 (A), rs10740055 (C) and rs7089424 (G) (dominant coding) was associated with odds ratio (OR) of 2.0 (1.0-4.0), 3.3 (1.3-8.6) and 1.9 (1.0-3.6), respectively, whereas the corresponding allelic ORs were equal to 1.2 (0.8-1.8), 1.3 (0.9-2.1) and 1.3 (0.9-2.1). AML was inversely related to carrying the variant allele of rs4132601 in IKZF1 (OR ¼ 0.5 (0.3-0.9)), on the contrary to what has been observed for ALL. [3] [4] [5] [6] The numbers were small, but none of the relationships seems to point specifically to any cytological subtype of AML (not shown). The associations were not modified after adjustment for parental professional category and for the environmental, immune or lifestyle factors associated with AML in the present study. [8] [9] [10] The study of the haplotypes, based on small numbers, suggested that the association with ARID5B mainly relied on rs10740055, reinforced with either none or both of the two other polymorphisms, and showed that the association with IKZF1 was driven by rs4132601 alone (Supplementary Table 1) .
Somatic deletion of IKZF1 is known to be associated with survival in childhood ALL. 11 In the present study, 1-and 5-year survival were similar between non-genotyped AML cases and genotyped AML cases, as well as between non-carriers and carriers of rs4132601 variant. Therefore, selection of surviving AML case is unlikely to explain our results.
A recent candidate gene study reported a significant association between infant AML and rs11978267 in IKZF1 (allelic OR equal to 1.8 (1.2-2.6)). 12 The authors did not investigate rs11978267 in IKZF1 and they reported no association between ARID5B SNPs and infant AML. The sample size of the present study did not allow restriction of the analysis to the children o1-year-old.
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